Literature DB >> 20132315

Association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set shifting in healthy individuals.

B T Baune1, T Suslow, C Beśte, E Birosova, K Domschke, C Sehlmeyer, C Konrad.   

Abstract

Set-shifting and maintenance are complex cognitive processes, which are often impaired in schizophrenia. The genetic basis of these processes is poorly understood. We aimed to investigate the association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set-shifting in healthy individuals. The relationship between 14 selected single nucleotide polymorphisms (SNPs) of the GRM3 gene and cognitive set-shifting as measured by perseverative errors using the modified card sorting test (MCST) was analysed in a sample of N = 98 young healthy individuals (mean age in years: 22.7 +/- 0.19). Results show that SNP rs17676277 is related to the performance on the MCST. Subjects with the TT genotype showed significantly less perseverative errors as compared with the AA (P = 0.025) and AT (P = 0.0005) and combined AA/AT genotypes (P = 0.0005). Haplotype analyses suggest the involvement of various SNPs of the GRM3 gene in perseverative error processing in a dominant model of inheritance. The findings strongly suggest that the genetic variation (rs17676277 and three haplotypes) in the metabotropic GRM3 is related to cognitive set-shifting in healthy individuals independent of working memory. However, because of a relatively small sample size for a genetic association study, the present results are tentative and require replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132315     DOI: 10.1111/j.1601-183X.2010.00573.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  7 in total

1.  Association of common variants in H2AFZ gene with schizophrenia and cognitive function in patients with schizophrenia.

Authors:  Ming Chang; Linyan Sun; Xinmei Liu; Wei Sun; Xuqun You
Journal:  J Hum Genet       Date:  2015-08-06       Impact factor: 3.172

2.  Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.

Authors:  Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-25       Impact factor: 5.270

Review 3.  Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.

Authors:  Adam G Walker; P Jeffrey Conn
Journal:  Curr Opin Pharmacol       Date:  2014-11-27       Impact factor: 5.547

4.  Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.

Authors:  Daiying Zuo; Tomasz Bzdega; Rafal T Olszewski; John R Moffett; Joseph H Neale
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

5.  NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.

Authors:  R T Olszewski; K J Janczura; S R Ball; J C Madore; K M Lavin; J C-M Lee; M J Lee; E K Der; T J Hark; P R Farago; C P Profaci; T Bzdega; J H Neale
Journal:  Transl Psychiatry       Date:  2012-07-31       Impact factor: 6.222

6.  Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate levels and neurocognition in non-smoking, active alcoholics.

Authors:  Yan Xia; Dongying Ma; Jian Hu; Chunling Tang; Zheng Wu; Lei Liu; Feng Xin
Journal:  Behav Brain Funct       Date:  2012-08-21       Impact factor: 3.759

7.  Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population.

Authors:  Wei Jia; Rui Zhang; Bin Wu; Zun-xiao Dai; Yong-sheng Zhu; Ping-ping Li; Feng Zhu
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.